Open AccessTherapeutic drug monitoring in inflammatory bowel disease
Author(s) -
Konstantinos Papamichael,
Adam S. Cheifetz
Publication year - 2019
Publication title -
current opinion in gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.165
H-Index - 83
eISSN - 1531-7056
pISSN - 0267-1379
DOI - 10.1097/mog.0000000000000536
Subject(s) - vedolizumab , therapeutic drug monitoring , medicine , infliximab , adalimumab , inflammatory bowel disease , ustekinumab , ulcerative colitis , crohn's disease , drug , tumor necrosis factor alpha , intensive care medicine , disease , pharmacology
The current review provides an updated overview on the role of therapeutic drug monitoring (TDM) of biological therapies in inflammatory bowel disease (IBD). We examine the data behind TDM for the antitumor necrosis factor agents, vedolizumab and ustekinumab, in patients with IBD. In addition, we discuss reactive vs. proactive TDM.